Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 61.00K | 63.00K | 54.00K | 68.00K | 130.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.00K | 63.00K | 54.00K | 68.00K | 130.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 61.00K | 63.00K | 54.00K | 68.00K | 130.00K |
| SG&A Expenses | 52.04M | 50.69M | 54.42M | 61.20M | 66.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.23M | -3.87M | -3.44M | -3.03M | -3.23M |
| Total Operating Expenses | 219.41M | 216.74M | 225.27M | 239.66M | 246.70M |
| Operating Income | -219.35M | -216.68M | -225.21M | -239.59M | -246.57M |
| Income Before Tax | -342.99M | -203.99M | -210.26M | -228.34M | -234.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -342.99 | -203.99 | -210.26 | -228.34 | -234.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -342.99M | -203.99M | -210.26M | -228.34M | -234.63M |
| EBIT | -219.35M | -216.68M | -225.21M | -239.59M | -246.57M |
| EBITDA | -199.72M | -197.02M | -205.13M | -219.34M | -226.32M |
| EPS Basic | -1.28 | -0.80 | -0.83 | -0.91 | -0.94 |
| Normalized Basic EPS | -0.46 | -0.47 | -0.49 | -0.53 | -0.69 |
| EPS Diluted | -1.28 | -0.80 | -0.83 | -0.91 | -0.94 |
| Normalized Diluted EPS | -0.46 | -0.47 | -0.49 | -0.53 | -0.69 |
| Average Basic Shares Outstanding | 1.05B | 1.02B | 1.01B | 1.01B | 1.00B |
| Average Diluted Shares Outstanding | 1.05B | 1.02B | 1.01B | 1.01B | 1.00B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
